Kyowa Kirin Australia general manager Simon Dawson says the company's "focus remains firmly on securing PBS reimbursement" of its CRYSVITA (burosumab) for the treatment of X-linked hypophosphataemia.
Kyowa Kirin marks registration of XLH treatment but 'focused' on PBS
September 14, 2021 Latest NewsBioPharma
Latest Video
New Stories
-
Biogen ANZ certified a 'Great Place to Work' for a fifth time
October 16, 2026 - - Latest News -
Tavneos to be withdrawn from Australia as CSL pulls vasculitis treatment
October 16, 2026 - - Latest News -
AI in HTA - survey reveals optimism and concern over a potential missed opportunity
October 16, 2026 - - Latest News -
England's chief scientific officer on the opportunity for Australia to get it right on genomics
October 15, 2026 - - Latest News -
The medicines gap costing Australian children time they can't get back
October 15, 2026 - - Latest News -
Brain cancer advocates return to Canberra 'to keep that ambition alive'
October 15, 2026 - - Latest News -
The effort to change an institution from within, works best when exit is possible
October 15, 2026 - - Latest News
